| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Influenza, Human | 20 | 2020 | 10779 | 0.91 | Why? |
| Milk Banks | 1 | 2021 | 99 | 0.77 | Why? |
| Enterovirus Infections | 6 | 2019 | 404 | 0.70 | Why? |
| France | 35 | 2021 | 12074 | 0.61 | Why? |
| Sentinel Surveillance | 3 | 2020 | 1093 | 0.54 | Why? |
| Respiratory Syncytial Virus Infections | 6 | 2021 | 1234 | 0.52 | Why? |
| Respiratory Syncytial Virus, Human | 5 | 2021 | 846 | 0.51 | Why? |
| Milk, Human | 1 | 2021 | 956 | 0.46 | Why? |
| Respiratory Tract Infections | 8 | 2021 | 6817 | 0.45 | Why? |
| Influenza Vaccines | 6 | 2017 | 2941 | 0.40 | Why? |
| Enterovirus D, Human | 3 | 2019 | 96 | 0.39 | Why? |
| Sequence Deletion | 3 | 2021 | 674 | 0.35 | Why? |
| Oseltamivir | 3 | 2018 | 583 | 0.29 | Why? |
| Epidemiological Monitoring | 2 | 2017 | 3493 | 0.28 | Why? |
| Tumor Suppressor Protein p53 | 3 | 2018 | 310 | 0.28 | Why? |
| Influenza A Virus, H1N1 Subtype | 5 | 2018 | 2984 | 0.27 | Why? |
| Influenza A virus | 4 | 2018 | 2234 | 0.27 | Why? |
| Meningitis, Aseptic | 1 | 2003 | 22 | 0.26 | Why? |
| Viral Nonstructural Proteins | 6 | 2020 | 4810 | 0.24 | Why? |
| Enterovirus B, Human | 1 | 2003 | 124 | 0.24 | Why? |
| Paralysis | 2 | 2019 | 92 | 0.22 | Why? |
| Naproxen | 1 | 2021 | 47 | 0.22 | Why? |
| Genetic Variation | 3 | 2021 | 3919 | 0.22 | Why? |
| Legionella | 1 | 2021 | 91 | 0.22 | Why? |
| Blood | 2 | 2020 | 274 | 0.22 | Why? |
| Zanamivir | 2 | 2018 | 63 | 0.22 | Why? |
| Influenza B virus | 2 | 2017 | 815 | 0.22 | Why? |
| Erythema Infectiosum | 1 | 2019 | 31 | 0.20 | Why? |
| Mycoplasma | 1 | 2019 | 36 | 0.20 | Why? |
| Parvovirus B19, Human | 1 | 2019 | 73 | 0.19 | Why? |
| Macaca fascicularis | 2 | 2021 | 1009 | 0.19 | Why? |
| Anelloviridae | 1 | 2018 | 34 | 0.19 | Why? |
| Nucleoproteins | 1 | 2021 | 223 | 0.19 | Why? |
| Mycoplasma Infections | 1 | 2019 | 65 | 0.19 | Why? |
| Virulence Factors | 2 | 2018 | 338 | 0.19 | Why? |
| Toxins, Biological | 1 | 2018 | 40 | 0.19 | Why? |
| Proto-Oncogene Proteins c-mdm2 | 1 | 2018 | 35 | 0.18 | Why? |
| Base Sequence | 3 | 2021 | 3581 | 0.18 | Why? |
| Interferon beta-1a | 1 | 2021 | 316 | 0.18 | Why? |
| DNA Virus Infections | 1 | 2018 | 88 | 0.18 | Why? |
| Peptide Chain Initiation, Translational | 1 | 2017 | 16 | 0.17 | Why? |
| Vaginal Neoplasms | 1 | 2017 | 39 | 0.17 | Why? |
| Seasons | 8 | 2021 | 4071 | 0.17 | Why? |
| High-Throughput Nucleotide Sequencing | 3 | 2018 | 3633 | 0.17 | Why? |
| Severe Combined Immunodeficiency | 1 | 2018 | 107 | 0.17 | Why? |
| DNA, Viral | 5 | 2019 | 2521 | 0.17 | Why? |
| Transplantation, Autologous | 1 | 2018 | 364 | 0.17 | Why? |
| Interferon Type I | 2 | 2021 | 2789 | 0.17 | Why? |
| Myelitis | 1 | 2019 | 122 | 0.17 | Why? |
| Paris | 1 | 2021 | 1287 | 0.16 | Why? |
| DNA Viruses | 1 | 2018 | 184 | 0.16 | Why? |
| Viral Fusion Proteins | 2 | 2018 | 399 | 0.16 | Why? |
| Capsid Proteins | 1 | 2019 | 365 | 0.16 | Why? |
| Mutant Proteins | 1 | 2017 | 328 | 0.15 | Why? |
| Roseolovirus Infections | 1 | 2017 | 131 | 0.15 | Why? |
| Humans | 73 | 2021 | 930598 | 0.15 | Why? |
| Cell Fusion | 1 | 2017 | 400 | 0.15 | Why? |
| Ribosomes | 1 | 2017 | 200 | 0.15 | Why? |
| Ubiquitin-Protein Ligases | 1 | 2018 | 249 | 0.15 | Why? |
| Chickenpox | 1 | 2018 | 194 | 0.15 | Why? |
| Disease Outbreaks | 4 | 2020 | 27595 | 0.14 | Why? |
| Viral Proteins | 4 | 2021 | 7370 | 0.14 | Why? |
| Herpesvirus 6, Human | 1 | 2017 | 162 | 0.14 | Why? |
| Public Health | 2 | 2020 | 16359 | 0.14 | Why? |
| Giant Cells | 1 | 2017 | 334 | 0.14 | Why? |
| Infant | 13 | 2021 | 30274 | 0.14 | Why? |
| Influenza A Virus, H5N1 Subtype | 1 | 2018 | 492 | 0.14 | Why? |
| Respiratory Mucosa | 2 | 2020 | 1522 | 0.14 | Why? |
| Viral Structural Proteins | 1 | 2018 | 491 | 0.14 | Why? |
| Pre-Exposure Prophylaxis | 2 | 2020 | 1138 | 0.14 | Why? |
| Metapneumovirus | 1 | 2017 | 465 | 0.14 | Why? |
| Common Cold | 2 | 2017 | 645 | 0.13 | Why? |
| Nose | 1 | 2020 | 1093 | 0.13 | Why? |
| Superinfection | 1 | 2018 | 459 | 0.13 | Why? |
| Epstein-Barr Virus Infections | 1 | 2018 | 366 | 0.13 | Why? |
| Bronchi | 1 | 2020 | 1048 | 0.13 | Why? |
| Stem Cell Transplantation | 1 | 2018 | 531 | 0.13 | Why? |
| Antiviral Agents | 10 | 2021 | 41703 | 0.13 | Why? |
| Child, Preschool | 13 | 2020 | 36283 | 0.12 | Why? |
| Rotavirus | 1 | 2016 | 329 | 0.12 | Why? |
| Influenza A Virus, H3N2 Subtype | 1 | 2017 | 572 | 0.12 | Why? |
| Protein Biosynthesis | 1 | 2017 | 653 | 0.12 | Why? |
| Pharyngitis | 1 | 2017 | 687 | 0.12 | Why? |
| Transportation | 1 | 2019 | 691 | 0.12 | Why? |
| Population Surveillance | 4 | 2020 | 4967 | 0.12 | Why? |
| Metagenomics | 1 | 2018 | 823 | 0.12 | Why? |
| Social Behavior | 1 | 2021 | 882 | 0.12 | Why? |
| Rotavirus Infections | 1 | 2016 | 355 | 0.12 | Why? |
| Epidemics | 3 | 2021 | 6407 | 0.11 | Why? |
| Genome, Viral | 4 | 2021 | 13157 | 0.11 | Why? |
| Pneumonia, Viral | 14 | 2020 | 243684 | 0.11 | Why? |
| Staphylococcus aureus | 1 | 2018 | 844 | 0.11 | Why? |
| Antibodies, Neutralizing | 5 | 2021 | 25288 | 0.11 | Why? |
| Coronavirus Infections | 15 | 2020 | 253789 | 0.11 | Why? |
| Phylogeny | 6 | 2021 | 13341 | 0.11 | Why? |
| Pneumonia, Bacterial | 1 | 2018 | 843 | 0.11 | Why? |
| Antibodies, Viral | 7 | 2021 | 51949 | 0.11 | Why? |
| Orthomyxoviridae Infections | 1 | 2018 | 1001 | 0.11 | Why? |
| RNA Viruses | 1 | 2018 | 824 | 0.11 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 1454 | 0.11 | Why? |
| Adult | 29 | 2021 | 244371 | 0.11 | Why? |
| NF-kappa B | 1 | 2018 | 1301 | 0.10 | Why? |
| Immune Evasion | 1 | 2021 | 2081 | 0.10 | Why? |
| Child | 15 | 2021 | 70012 | 0.10 | Why? |
| Autoantibodies | 1 | 2021 | 2094 | 0.10 | Why? |
| Aged | 25 | 2021 | 215776 | 0.10 | Why? |
| Lopinavir | 2 | 2021 | 4308 | 0.10 | Why? |
| Male | 32 | 2021 | 367725 | 0.10 | Why? |
| Viral Load | 8 | 2021 | 15850 | 0.10 | Why? |
| Pandemics | 16 | 2020 | 389249 | 0.10 | Why? |
| Middle Aged | 27 | 2021 | 270681 | 0.10 | Why? |
| Female | 32 | 2021 | 380317 | 0.09 | Why? |
| Adolescent | 15 | 2020 | 86841 | 0.09 | Why? |
| Young Adult | 15 | 2021 | 93724 | 0.09 | Why? |
| Coinfection | 4 | 2021 | 6820 | 0.09 | Why? |
| Amino Acid Sequence | 1 | 2020 | 6049 | 0.09 | Why? |
| Infant, Newborn | 7 | 2018 | 23105 | 0.09 | Why? |
| Aged, 80 and over | 15 | 2021 | 88759 | 0.09 | Why? |
| Public Policy | 1 | 2020 | 1894 | 0.09 | Why? |
| Cell Line | 6 | 2021 | 12040 | 0.09 | Why? |
| Vero Cells | 5 | 2021 | 14117 | 0.08 | Why? |
| Drug Synergism | 2 | 2020 | 833 | 0.08 | Why? |
| Cytokines | 5 | 2021 | 15010 | 0.08 | Why? |
| Hydroxychloroquine | 2 | 2021 | 12447 | 0.08 | Why? |
| Real-Time Polymerase Chain Reaction | 4 | 2020 | 11367 | 0.08 | Why? |
| Headache | 1 | 2017 | 2257 | 0.08 | Why? |
| Viruses | 1 | 2020 | 2238 | 0.08 | Why? |
| Betacoronavirus | 12 | 2020 | 204454 | 0.08 | Why? |
| Ritonavir | 1 | 2021 | 4212 | 0.08 | Why? |
| Fatigue | 1 | 2017 | 2479 | 0.08 | Why? |
| Neuraminidase | 2 | 2018 | 289 | 0.08 | Why? |
| Databases, Factual | 2 | 2020 | 6248 | 0.08 | Why? |
| Genotype | 4 | 2019 | 4697 | 0.07 | Why? |
| Monocytes | 1 | 2018 | 2978 | 0.07 | Why? |
| Neutralization Tests | 4 | 2021 | 6698 | 0.07 | Why? |
| Communicable Diseases, Emerging | 2 | 2019 | 2523 | 0.07 | Why? |
| Reassortant Viruses | 2 | 2018 | 287 | 0.07 | Why? |
| Drug Repositioning | 2 | 2021 | 5683 | 0.07 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 7868 | 0.07 | Why? |
| Point-of-Care Testing | 1 | 2017 | 2782 | 0.07 | Why? |
| Vaccination | 3 | 2020 | 19050 | 0.07 | Why? |
| Animals | 11 | 2021 | 78931 | 0.07 | Why? |
| Community-Acquired Infections | 1 | 1996 | 2328 | 0.07 | Why? |
| Ambulatory Care | 1 | 2021 | 4947 | 0.06 | Why? |
| Dyspnea | 1 | 2017 | 3847 | 0.06 | Why? |
| Epithelial Cells | 2 | 2017 | 3508 | 0.06 | Why? |
| Mass Screening | 2 | 2021 | 8005 | 0.06 | Why? |
| Serotyping | 1 | 2003 | 154 | 0.06 | Why? |
| Prospective Studies | 7 | 2021 | 43301 | 0.06 | Why? |
| Cough | 1 | 2017 | 4891 | 0.06 | Why? |
| Travel | 3 | 2020 | 7220 | 0.06 | Why? |
| Signal Transduction | 3 | 2018 | 7207 | 0.06 | Why? |
| RNA, Messenger | 1 | 2017 | 5131 | 0.06 | Why? |
| RNA, Viral | 6 | 2020 | 32276 | 0.06 | Why? |
| Health Personnel | 3 | 2021 | 29646 | 0.06 | Why? |
| Mutation, Missense | 2 | 2018 | 863 | 0.06 | Why? |
| Transplant Recipients | 1 | 2018 | 4982 | 0.06 | Why? |
| Feces | 3 | 2020 | 4235 | 0.06 | Why? |
| Models, Theoretical | 1 | 2021 | 6659 | 0.06 | Why? |
| Emergency Service, Hospital | 2 | 2017 | 14232 | 0.06 | Why? |
| Virus Replication | 5 | 2021 | 14331 | 0.06 | Why? |
| Frameshift Mutation | 1 | 2021 | 158 | 0.06 | Why? |
| Biosurveillance | 1 | 2021 | 25 | 0.06 | Why? |
| Diltiazem | 1 | 2020 | 22 | 0.06 | Why? |
| Drug Antagonism | 1 | 2020 | 24 | 0.06 | Why? |
| Drug Resistance, Viral | 2 | 2018 | 1083 | 0.05 | Why? |
| Communicable Disease Control | 2 | 2021 | 29620 | 0.05 | Why? |
| Specimen Handling | 1 | 2019 | 6190 | 0.05 | Why? |
| Drug Combinations | 2 | 2021 | 3852 | 0.05 | Why? |
| Iceland | 1 | 2021 | 314 | 0.05 | Why? |
| Coercion | 1 | 2020 | 57 | 0.05 | Why? |
| Dogs | 2 | 2018 | 2529 | 0.05 | Why? |
| Sensitivity and Specificity | 2 | 2021 | 22971 | 0.05 | Why? |
| Health Policy | 1 | 2020 | 6242 | 0.05 | Why? |
| Airway Remodeling | 1 | 2020 | 111 | 0.05 | Why? |
| Fever | 1 | 2017 | 7795 | 0.05 | Why? |
| Ureaplasma urealyticum | 1 | 2019 | 10 | 0.05 | Why? |
| Mycoplasma hominis | 1 | 2019 | 15 | 0.05 | Why? |
| Sequence Analysis, DNA | 2 | 2019 | 2830 | 0.05 | Why? |
| Ureaplasma Infections | 1 | 2019 | 12 | 0.05 | Why? |
| Berberine | 1 | 2020 | 98 | 0.05 | Why? |
| Europe | 3 | 2021 | 12702 | 0.05 | Why? |
| Desiccation | 1 | 2019 | 38 | 0.05 | Why? |
| Cross Infection | 1 | 2021 | 8675 | 0.05 | Why? |
| Reproductive Tract Infections | 1 | 2019 | 45 | 0.05 | Why? |
| Postoperative Complications | 1 | 2018 | 5861 | 0.05 | Why? |
| Virus Diseases | 1 | 1996 | 3779 | 0.05 | Why? |
| Pre-Analytical Phase | 1 | 2019 | 36 | 0.05 | Why? |
| Basic Reproduction Number | 2 | 2021 | 2676 | 0.05 | Why? |
| Viral Vaccines | 1 | 2020 | 7560 | 0.05 | Why? |
| Gammapapillomavirus | 1 | 2017 | 7 | 0.04 | Why? |
| Kaplan-Meier Estimate | 2 | 2018 | 4260 | 0.04 | Why? |
| Squamous Intraepithelial Lesions of the Cervix | 1 | 2017 | 21 | 0.04 | Why? |
| Lost to Follow-Up | 1 | 2017 | 79 | 0.04 | Why? |
| Multivariate Analysis | 2 | 2020 | 5440 | 0.04 | Why? |
| Kidney Transplantation | 1 | 2018 | 5397 | 0.04 | Why? |
| Disease Models, Animal | 3 | 2021 | 10998 | 0.04 | Why? |
| Molecular Typing | 1 | 2019 | 280 | 0.04 | Why? |
| Automation, Laboratory | 1 | 2020 | 536 | 0.04 | Why? |
| Cord Blood Stem Cell Transplantation | 1 | 2018 | 143 | 0.04 | Why? |
| Urine | 1 | 2020 | 469 | 0.04 | Why? |
| World Health Organization | 2 | 2020 | 4213 | 0.04 | Why? |
| Virus Integration | 1 | 2017 | 96 | 0.04 | Why? |
| In Vitro Techniques | 1 | 2020 | 1027 | 0.04 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.04 | Why? |
| Colposcopy | 1 | 2017 | 89 | 0.04 | Why? |
| Proteasome Endopeptidase Complex | 1 | 2018 | 249 | 0.04 | Why? |
| Protein Transport | 1 | 2018 | 487 | 0.04 | Why? |
| Cyclosporine | 1 | 2020 | 449 | 0.04 | Why? |
| Immunoglobulins, Intravenous | 2 | 2018 | 2705 | 0.04 | Why? |
| Reproducibility of Results | 3 | 2020 | 11304 | 0.04 | Why? |
| Time Factors | 4 | 2021 | 31397 | 0.04 | Why? |
| Hospitalization | 7 | 2021 | 54280 | 0.04 | Why? |
| Drug Therapy | 1 | 2018 | 280 | 0.04 | Why? |
| Cervical Intraepithelial Neoplasia | 1 | 2017 | 114 | 0.04 | Why? |
| Reference Standards | 1 | 2020 | 1163 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2021 | 15978 | 0.04 | Why? |
| Serologic Tests | 2 | 2020 | 4359 | 0.04 | Why? |
| Virology | 1 | 2020 | 489 | 0.04 | Why? |
| Vaccine Potency | 1 | 2017 | 339 | 0.04 | Why? |
| Trachea | 1 | 2021 | 894 | 0.04 | Why? |
| Phosphatidylinositol 3-Kinases | 1 | 2018 | 347 | 0.04 | Why? |
| Nasal Cavity | 1 | 2021 | 909 | 0.04 | Why? |
| Longitudinal Studies | 2 | 2021 | 9893 | 0.04 | Why? |
| Proto-Oncogene Proteins c-akt | 1 | 2018 | 372 | 0.04 | Why? |
| Pharynx | 1 | 2003 | 1544 | 0.04 | Why? |
| Adenovirus Infections, Human | 1 | 1996 | 145 | 0.04 | Why? |
| Protein Stability | 1 | 2018 | 756 | 0.04 | Why? |
| Madin Darby Canine Kidney Cells | 1 | 2017 | 640 | 0.04 | Why? |
| Proportional Hazards Models | 2 | 2018 | 6543 | 0.04 | Why? |
| Intensive Care Units | 2 | 2021 | 29594 | 0.04 | Why? |
| Quality Control | 1 | 2018 | 628 | 0.04 | Why? |
| DNA Mutational Analysis | 1 | 2017 | 581 | 0.03 | Why? |
| Databases, Genetic | 1 | 2021 | 1127 | 0.03 | Why? |
| HIV Infections | 1 | 2020 | 11620 | 0.03 | Why? |
| Vagina | 1 | 2017 | 327 | 0.03 | Why? |
| Telecommunications | 1 | 2020 | 551 | 0.03 | Why? |
| Treatment Failure | 1 | 2020 | 2106 | 0.03 | Why? |
| Stillbirth | 1 | 2018 | 544 | 0.03 | Why? |
| Amino Acid Substitution | 1 | 2021 | 1706 | 0.03 | Why? |
| Polymerase Chain Reaction | 2 | 2019 | 6740 | 0.03 | Why? |
| Paramyxoviridae Infections | 1 | 1996 | 364 | 0.03 | Why? |
| Reverse Genetics | 1 | 2017 | 439 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.03 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.03 | Why? |
| Infant, Low Birth Weight | 1 | 2014 | 243 | 0.03 | Why? |
| Urinary Tract Infections | 1 | 2019 | 534 | 0.03 | Why? |
| Biological Specimen Banks | 1 | 2021 | 1142 | 0.03 | Why? |
| Retrospective Studies | 6 | 2020 | 105322 | 0.03 | Why? |
| Molecular Sequence Data | 1 | 2018 | 3198 | 0.03 | Why? |
| Coronavirus | 2 | 2020 | 18339 | 0.03 | Why? |
| Papillomaviridae | 1 | 2017 | 404 | 0.03 | Why? |
| Pregnancy Complications, Infectious | 1 | 2018 | 11559 | 0.03 | Why? |
| Adenosine Monophosphate | 2 | 2020 | 5652 | 0.03 | Why? |
| Alanine | 2 | 2020 | 5687 | 0.03 | Why? |
| Cell Survival | 1 | 2018 | 1581 | 0.03 | Why? |
| Safety | 1 | 2020 | 1583 | 0.03 | Why? |
| Respiratory Tract Diseases | 1 | 2021 | 1061 | 0.03 | Why? |
| Limit of Detection | 1 | 2020 | 2698 | 0.03 | Why? |
| Morbidity | 1 | 2018 | 1426 | 0.03 | Why? |
| Gene Expression Regulation, Viral | 1 | 2018 | 925 | 0.03 | Why? |
| Kinetics | 1 | 2020 | 3238 | 0.03 | Why? |
| Cluster Analysis | 1 | 2020 | 3001 | 0.03 | Why? |
| Indoles | 1 | 2020 | 1243 | 0.03 | Why? |
| High-Throughput Screening Assays | 1 | 2020 | 1783 | 0.03 | Why? |
| Hemagglutination Inhibition Tests | 1 | 2011 | 191 | 0.03 | Why? |
| Virulence | 1 | 2018 | 2172 | 0.03 | Why? |
| Nasopharynx | 2 | 2021 | 10224 | 0.03 | Why? |
| A549 Cells | 1 | 2017 | 2066 | 0.03 | Why? |
| Administration, Inhalation | 1 | 2017 | 1647 | 0.03 | Why? |
| Sequence Analysis, RNA | 1 | 2020 | 2290 | 0.03 | Why? |
| United Arab Emirates | 1 | 2013 | 704 | 0.03 | Why? |
| Incidence | 3 | 2020 | 25622 | 0.03 | Why? |
| Congresses as Topic | 1 | 2020 | 1347 | 0.03 | Why? |
| Treatment Outcome | 4 | 2021 | 51732 | 0.03 | Why? |
| Recombination, Genetic | 1 | 2017 | 1265 | 0.03 | Why? |
| Immunity | 1 | 2021 | 2651 | 0.03 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.02 | Why? |
| Motivation | 1 | 2020 | 1640 | 0.02 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2017 | 13720 | 0.02 | Why? |
| United States | 1 | 2017 | 46150 | 0.02 | Why? |
| Infant, Premature | 1 | 2014 | 883 | 0.02 | Why? |
| Multiple Myeloma | 1 | 2018 | 1064 | 0.02 | Why? |
| Primary Health Care | 2 | 2017 | 4839 | 0.02 | Why? |
| Risk Factors | 4 | 2020 | 71621 | 0.02 | Why? |
| Blotting, Western | 1 | 2011 | 863 | 0.02 | Why? |
| Uterine Cervical Neoplasms | 1 | 2017 | 842 | 0.02 | Why? |
| Papillomavirus Infections | 1 | 2017 | 861 | 0.02 | Why? |
| Orthomyxoviridae | 1 | 2017 | 1168 | 0.02 | Why? |
| Drug Design | 1 | 2020 | 2627 | 0.02 | Why? |
| Medication Adherence | 1 | 2017 | 1270 | 0.02 | Why? |
| Bacteria | 1 | 2018 | 1897 | 0.02 | Why? |
| Viral Envelope Proteins | 1 | 2020 | 3539 | 0.02 | Why? |
| Immunity, Cellular | 1 | 2020 | 3614 | 0.02 | Why? |
| Inflammation | 2 | 2021 | 13255 | 0.02 | Why? |
| Gene Expression | 1 | 2018 | 3332 | 0.02 | Why? |
| Macaca mulatta | 1 | 2017 | 3716 | 0.02 | Why? |
| Age Distribution | 1 | 1996 | 3567 | 0.02 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.02 | Why? |
| International Cooperation | 1 | 2020 | 3436 | 0.02 | Why? |
| Global Health | 2 | 2020 | 13911 | 0.02 | Why? |
| Protein Conformation | 1 | 2017 | 4386 | 0.02 | Why? |
| Pregnancy | 2 | 2019 | 23879 | 0.02 | Why? |
| Double-Blind Method | 1 | 2017 | 5988 | 0.02 | Why? |
| Biological Products | 1 | 2020 | 2331 | 0.02 | Why? |
| Hospitals, University | 1 | 2018 | 4173 | 0.02 | Why? |
| Disseminated Intravascular Coagulation | 1 | 2014 | 994 | 0.02 | Why? |
| Logistic Models | 1 | 2020 | 9089 | 0.02 | Why? |
| Molecular Docking Simulation | 1 | 2021 | 6902 | 0.02 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.02 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.02 | Why? |
| Down-Regulation | 1 | 2011 | 1416 | 0.02 | Why? |
| Prevalence | 2 | 2018 | 25773 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2019 | 7220 | 0.02 | Why? |
| Protein Domains | 1 | 2017 | 6563 | 0.02 | Why? |
| Outpatients | 1 | 2017 | 3417 | 0.02 | Why? |
| Fatal Outcome | 1 | 2013 | 3438 | 0.02 | Why? |
| Models, Molecular | 1 | 2017 | 7616 | 0.02 | Why? |
| Models, Biological | 1 | 2020 | 4907 | 0.02 | Why? |
| China | 2 | 2020 | 50654 | 0.02 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.02 | Why? |
| Antineoplastic Agents | 1 | 2018 | 3550 | 0.02 | Why? |
| Internet | 1 | 2020 | 6204 | 0.01 | Why? |
| Immunity, Innate | 1 | 2020 | 6570 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.01 | Why? |
| Molecular Diagnostic Techniques | 1 | 2017 | 4239 | 0.01 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.01 | Why? |
| Thrombocytopenia | 1 | 2014 | 2093 | 0.01 | Why? |
| Urban Population | 1 | 2011 | 2000 | 0.01 | Why? |
| Immunocompromised Host | 1 | 2017 | 5150 | 0.01 | Why? |
| Cross Reactions | 1 | 2011 | 4374 | 0.01 | Why? |
| Gene Expression Profiling | 1 | 2011 | 3788 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.01 | Why? |
| Mice | 1 | 2018 | 21357 | 0.01 | Why? |
| Liver Diseases | 1 | 2014 | 2698 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 9706 | 0.01 | Why? |
| Cohort Studies | 1 | 2021 | 36005 | 0.01 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.01 | Why? |
| Severity of Illness Index | 2 | 2016 | 48226 | 0.01 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.01 | Why? |
| Seroepidemiologic Studies | 1 | 2011 | 10017 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Contact Tracing | 1 | 2013 | 8448 | 0.01 | Why? |
| Disease Transmission, Infectious | 1 | 2013 | 9044 | 0.01 | Why? |
| Age Factors | 1 | 2011 | 21039 | 0.01 | Why? |
| Lung | 1 | 2018 | 31049 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2017 | 53120 | 0.01 | Why? |